FASL Antikörper (FITC)

Produktnummer ABIN1105947

Produktdetails anti-FASL Antikörper (FITC)

Target: FASL (Fas Ligand (TNF Superfamily, Member 6) (FASL))

Reaktivität: Human

Wirt: Hamster

Klonalität: Monoklonal

Konjugat: Dieser FASL Antikörper ist konjugiert mit FITC

Applikation: Flow Cytometry (FACS)

Spezifität: This antibody reacts with Fas Ligand.

Kreuzreaktivität (Details): Species reactivity (tested):Human

Aufreinigung: Protein A agarose

Immunogen: Recombinant human Fas Ligand

Klon: GE 4-90

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: PBS, 0.09 % NaN3, 1 % BSA

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Store at 2 - 8 °C.

Details zu FASL

Target: FASL (Fas Ligand (TNF Superfamily, Member 6) (FASL))

Andere Bezeichnung: CD178 / Fas Ligand (FASL Produkte)

Synonyme: ALPS1B antikoerper, APT1LG1 antikoerper, APTL antikoerper, CD178 antikoerper, CD95-L antikoerper, CD95L antikoerper, FASL antikoerper, TNFSF6 antikoerper, fasl antikoerper, Fas-L antikoerper, Faslg antikoerper, Tnfsf6 antikoerper, gld antikoerper, Apt1Lg1 antikoerper, Fasl antikoerper, FASLG antikoerper, zgc:162027 antikoerper, Fas ligand antikoerper, Fas ligand L homeolog antikoerper, Fas ligand (TNF superfamily, member 6) antikoerper, FASLG antikoerper, faslg.L antikoerper, Fasl antikoerper, Faslg antikoerper, faslg antikoerper

Hintergrund: Fas ligand (FasL/CD178/CD95L) is a type II-membrane protein, belonging the tumor necrosis factor (TNF)/nerve growth factor (NGF) family. It is known that engagement of Fas (receptor of FasL) by FasL causes apoptotic cell death. FasL is predominantly expressed in activated T lymphocytes and Natural Killer (NK) cells and expressed in the tissues of the immune-privilege sites such as the testis and eye. On the other hand, Fas is expressed in various tissues with abundant expression in the thymus, liver, heart, and kidney. Furthermore, a variety of cancers such as melanomas were found to express FasL in addition to Fas. It is said that, Fas/FasL system is involved in the deletion of dangerous activated or autoreactive T and B cells, and in tern play a role in human diseases such as fulminant hepatitis, AIDS, cancers and other diseases involving CTL-induced tissue destruction. Furthermore, FasL can be used as an immune-suppressive agent. Rejection of transplants is mediated by activated T cells that may express functional Fas. If a transplanted tissue is engineered to express FasL or is co-transplanted with FasL-expressing cells, the transplant may be tolerated.Synonyms: APT1LG1, APTL, Apoptosis antigen ligand, CD95L protein, FASL, FASLG, Fas antigen ligand, TNFSF6, Tumor necrosis factor ligand superfamily member 6

Gen-ID: 356

NCBI Accession: NP_000630

UniProt: P48023

Pathways: Apoptose, EGFR Signaling Pathway, Production of Molecular Mediator of Immune Response, Positive Regulation of Endopeptidase Activity